Q32 Bio (QTTB) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on therapies for alopecia areata and autoimmune diseases.

• Lead candidate bempikibart is a monoclonal antibody targeting interleukin-7 receptor alpha, with Phase 2a trials completed for alopecia areata and atopic dermatitis.

• Corporate restructuring in February 2025 shifted focus to bempikibart, with non-core assets sold or retained for strategic review.

• Incorporated in Delaware, with a recent merger and name change in March 2024; common stock trades on Nasdaq under QTTB.

Financial performance and metrics

• Designated as a smaller reporting company, eligible for scaled disclosure requirements due to market cap and revenue thresholds.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including working capital, R&D, clinical development, commercial efforts, administrative expenses, acquisitions, and business opportunities.